ALK Chief: This is why we will conquer the US
ALK’s CEO Jens Bager sees three or four tangible advantages that the Danish company would have over a big pharma rival, if they both win the right to market a pill against grass pollen allergy in the US.
by Henrik Tüchsen
As the CEO of Danish allergy group ALK attempts to soften the rhetoric concerning the company’s position on the market for grass pollen allergy treatments in the US with new oral drug Grastek, the confidence nevertheless shines through when talk turns to rival drug Oralair from French company Stallergenes. We will take the lead, seems to be the indirect message from CEO Jens Bager.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
ALK given new date for crucial FDA meeting
For abonnenter
Danish inventor is ready to go overseas
For abonnenter
